{"entity":{"id":"nct02264678","kind":"trial","name":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is active not recruiting.","summary":"The registry lists NCT02264678 as active not recruiting, last updated 2026-07-24. Enrolment is 358 actual participants. Interventions: Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin. Primary measures include The number of subjects with adverse events/serious adverse events; Module 4 only: Effect of food on ceralasertib absorption by Intensive PK assessments after a single oral dose of ceralasertib (Part A). No results are posted in the registry; this does not exclude separate publications.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT02264678","url":"https://clinicaltrials.gov/study/NCT02264678"}],"tags":[],"related":[],"cancers":["breast-cancer","ovarian","gastric","nsclc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02264678","phase":"1","setting":"A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.","sponsor":"AstraZeneca","started":"2014-10-31","startedType":"actual","enrolled":358,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02264678/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}]}}